Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NMRA |
---|---|---|
09:32 ET | 1348 | 9.5 |
09:34 ET | 6487 | 9.435 |
09:38 ET | 1155 | 9.395 |
09:39 ET | 1209 | 9.48 |
09:41 ET | 500 | 9.48 |
09:43 ET | 345 | 9.47 |
09:45 ET | 300 | 9.47 |
09:48 ET | 933 | 9.36 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Neumora Therapeutics Inc | 1.5B | -6.1x | --- |
Belite Bio Inc | 1.5B | -40.9x | --- |
Edgewise Therapeutics Inc | 1.6B | -11.3x | --- |
Kura Oncology Inc | 1.6B | -9.8x | --- |
Soleno Therapeutics Inc | 1.4B | -15.1x | --- |
Akero Therapeutics Inc | 1.6B | -7.4x | --- |
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 159.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.55 |
Book Value | $2.95 |
P/E Ratio | -6.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.